北京治疗白癜风的医院哪家好 http://m.39.net/pf/bdfyy/IdecabtageneVicleucelinRelapsedandRefractoryMultipleMyelomaNEJMresearch-articleFeb25,
8),-./NEJMoa本文由“天纳”临床学术信息人工智能系统自动翻译BackgroundIdecabtagenevicleucel(ide-cel,alsocalledbb),aB-cellmaturationantigen–directedchimericantigenreceptor(CAR)T-celltherapy,hasshownclinicalactivitywithexpectedCART-celltoxiceffectsinpatientswithrelapsedandrefractorymultiplemyeloma.idecabatgene-vicleucel（ide-cel，又称bb）是一种B细胞成熟抗原导向的嵌合抗原受体（CAR）T细胞疗法，在复发和难治性多发性骨髓瘤患者中显示出预期的CAR-T细胞*性作用。MethodsInthisphase2study,wesoughttoconfirmtheefficacyandsafetyofide-celinpatientswithrelapsedandrefractorymyeloma.Patientswithdiseaseafteratleastthreepreviousregimensincludingaproteasomeinhibitor,animmunomodulatoryagent,andananti-CD38antibodywereenrolled.Patientsreceivedide-celtargetdosesof×to×CAR-positive(CAR)Tcells.Theprimaryendpointwasanoverallresponse(partialresponseorbetter);akeysecondaryendpointwasa
